Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Alcon AG
Regeneron Pharmaceuticals Inc

Price performance

Price movement over the last 24 hours

Key statistics

Alcon AG vs Regeneron Pharmaceuticals Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Regeneron Pharmaceuticals Inc trades at $662.85 (market cap $70.90B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.2× Alcon AG's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.

ALCREGN
Market Cap
$32.69B$70.90B
Sector
HealthHealth
52-Week High
$92.22$812.27
52-Week Low
$62.02$542.52
Enterprise Value
$36.28B$64.85B
Dividend Yield
0.54%0.56%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN